BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37679770)

  • 21. [
    Kobayashi M; Mizutani A; Nishi K; Muranaka Y; Nishii R; Shikano N; Nakanishi T; Tamai I; Kleinerman ES; Kawai K
    Nucl Med Biol; 2020; 90-91():49-54. PubMed ID: 33032192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
    Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB
    J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cotransfecting norepinephrine transporter and vesicular monoamine transporter 2 genes for increased retention of metaiodobenzylguanidine labeled with iodine 131 in malignant hepatocarcinoma cells.
    Zhao Y; Zhong X; Ou X; Cai H; Wu X; Huang R
    Front Med; 2017 Mar; 11(1):120-128. PubMed ID: 28213878
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Turnock S; Turton DR; Martins CD; Chesler L; Wilson TC; Gouverneur V; Smith G; Kramer-Marek G
    Sci Rep; 2020 Dec; 10(1):20918. PubMed ID: 33262374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action.
    Hu C; Xia H; Bai S; Zhao J; Edwards H; Li X; Yang Y; Lyu J; Wang G; Zhan Y; Dong Y; Ge Y
    J Cell Mol Med; 2020 Jul; 24(13):7239-7253. PubMed ID: 32459381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to
    Batra V; Gikandi A; Pawel B; Martinez D; Granger MM; Marachelian A; Park JR; Maris JM; Vo KT; Matthay KK; DuBois SG
    Pediatr Blood Cancer; 2024 Jan; 71(1):e30743. PubMed ID: 37885116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors.
    Grünwald F; Ezziddin S
    Semin Nucl Med; 2010 Mar; 40(2):153-63. PubMed ID: 20113683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
    Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CUDC-907 exhibits potent antitumor effects against ovarian cancer through multiple in vivo and in vitro mechanisms.
    Wang Y; Wen J; Sun X; Sun Y; Liu Y; Cheng X; Wu W; Liu Q; Ren F
    Cancer Chemother Pharmacol; 2024 Apr; 93(4):295-306. PubMed ID: 37938423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical assessment of strategies for enhancement of metaiodobenzylguanidine therapy of neuroendocrine tumors.
    Mairs RJ; Boyd M
    Semin Nucl Med; 2011 Sep; 41(5):334-44. PubMed ID: 21803183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
    Qian C; Lai CJ; Bao R; Wang DG; Wang J; Xu GX; Atoyan R; Qu H; Yin L; Samson M; Zifcak B; Ma AW; DellaRocca S; Borek M; Zhai HX; Cai X; Voi M
    Clin Cancer Res; 2012 Aug; 18(15):4104-13. PubMed ID: 22693356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of monoamine transporters in neuroblastoma cell lines: correlations to meta-iodobenzylguanidine (MIBG) uptake and tyrosine hydroxylase gene expression.
    Lode HN; Bruchelt G; Seitz G; Gebhardt S; Gekeler V; Niethammer D; Beck J
    Eur J Cancer; 1995; 31A(4):586-90. PubMed ID: 7576974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma.
    Erlich RB; Kherrouche Z; Rickwood D; Endo-Munoz L; Cameron S; Dahler A; Hazar-Rethinam M; de Long LM; Wooley K; Guminski A; Saunders NA
    Br J Cancer; 2012 Jan; 106(1):107-15. PubMed ID: 22116303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of diagnostic value of I-123 MIBG and high-dose I-131 MIBG scintigraphy including incremental value of SPECT/CT over planar image in patients with malignant pheochromocytoma/paraganglioma and neuroblastoma.
    Fukuoka M; Taki J; Mochizuki T; Kinuya S
    Clin Nucl Med; 2011 Jan; 36(1):1-7. PubMed ID: 21157198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells.
    Okabe S; Tanaka Y; Moriyama M; Gotoh A
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):401-412. PubMed ID: 31901955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group.
    Temple W; Mendelsohn L; Kim GE; Nekritz E; Gustafson WC; Lin L; Giacomini K; Naranjo A; Van Ryn C; Yanik GA; Kreissman SG; Hogarty M; Matthay KK; DuBois SG
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):474-481. PubMed ID: 26338179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter.
    McCluskey AG; Boyd M; Ross SC; Cosimo E; Clark AM; Angerson WJ; Gaze MN; Mairs RJ
    Clin Cancer Res; 2005 Nov; 11(21):7929-37. PubMed ID: 16278418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Norepinephrine Transporter as a Target for Imaging and Therapy.
    Pandit-Taskar N; Modak S
    J Nucl Med; 2017 Sep; 58(Suppl 2):39S-53S. PubMed ID: 28864611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meta-[131I]iodobenzylguanidine in the scintigraphic evaluation of neural crest tumors.
    Zagar I; Han R; Mitrovic S
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):13-6. PubMed ID: 9002742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meta-iodobenzylguanidine in children.
    Gelfand MJ
    Semin Nucl Med; 1993 Jul; 23(3):231-42. PubMed ID: 8378796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.